Onset and duration are distinct but connected PK/PD timing constructs. The onset definition describes when a pharmacological effect begins to emerge, while the duration definition describes how long that effect remains within a defined pharmacologically relevant window. For sildenafil, the pkpd overview framework separates pharmacokinetics, which describes drug concentration and exposure over time, from pharmacodynamics, which describes the biological response associated with that exposure. The time to effect concept therefore reflects a sequence rather than one isolated event. The onset absorption phase establishes systemic input, the onset distribution phase describes movement between compartments, and onset plasma levels describe the early exposure trajectory. The onset cmax relation connects that trajectory to peak concentration without equating Cmax with onset. Duration concerns the subsequent effect window, exposure persistence, duration metabolism, duration elimination, duration half-life, and duration plasma levels.
Onset emerges from the ascending portion of a PK/PD trajectory. After oral administration, absorption introduces sildenafil into systemic circulation, plasma concentrations rise, and distribution contributes to movement between plasma and relevant compartments. As exposure develops, the concentration–effect relationship determines when a pharmacodynamic response becomes detectable or enters a defined response-relevant range. This transition is often described conceptually as threshold crossing, although a threshold need not be a single universal concentration. Duration emerges from the later portion of the same trajectory. Once effect has appeared, exposure persistence and the concentration–response relationship determine how long relevant activity continues. Metabolism, clearance, and elimination progressively reduce systemic exposure, while distribution and effect-site relationships may influence the relationship between plasma concentration and response. An onset vs duration graph can illustrate these different regions of the time course. The distinction is important because a change in early absorption does not necessarily produce an equivalent change in later elimination. Likewise, altered clearance may change persistence without materially changing the initial absorption phase.
PK/PD timing fundamentals explain why onset and duration should be interpreted mechanistically rather than subjectively. The variability factors framework considers differences in absorption, distribution, metabolism, elimination, interactions, and pharmacodynamic sensitivity that can shift one or more portions of the time course. Timing consistency describes how reproducibly a temporal pattern occurs across observations; it does not imply an identical clock-time response in every circumstance. A mechanistic comparison therefore asks which layer is responsible for a timing difference. An earlier response may reflect altered absorption or early exposure, while longer persistence may reflect exposure decline, metabolism, clearance, or the concentration–effect relationship. These are descriptive relationships, not subjective ratings. The purpose of this page is to establish the fundamental distinction between onset and duration, explain their PK/PD origins, and connect the two constructs through exposure, effect windows, variability, and timing interpretation for sildenafil.
The fundamental distinction between onset and duration begins with the difference between effect emergence and effect persistence. The onset definition identifies the point at which a pharmacological response becomes observable or pharmacologically meaningful. The duration definition identifies the subsequent interval during which that response remains within a defined effect range. For sildenafil, these constructs are interpreted through the pkpd overview, which separates pharmacokinetic exposure from pharmacodynamic response. Pharmacokinetics describes the concentration–time profile produced by drug input and disposition. Pharmacodynamics describes how that exposure relates to biological activity. Onset therefore belongs primarily to the ascending exposure–response sequence, while duration belongs primarily to the persistence and decline sequence. The two are connected by the same drug concentration profile but are not interchangeable measurements. A timing difference must be interpreted according to which portion of the PK/PD trajectory has changed.
Onset begins with input and early systemic exposure. The onset absorption phase describes the process through which sildenafil enters systemic circulation after oral administration. The onset distribution phase describes subsequent movement between plasma and other compartments. As exposure develops, plasma concentration rises and the pharmacodynamic response becomes associated with the concentration–effect relationship. Threshold crossing is a useful conceptual description of the point at which exposure enters a response-relevant range, although the underlying response may be gradual. Duration follows a different portion of the same trajectory. The duration metabolism concept describes metabolic transformation that contributes to changes in parent-drug exposure. The duration elimination concept describes removal of drug from the body through combined metabolic and excretory processes. These mechanisms help explain why effect persistence depends on more than the time of initial effect emergence.
The PK/PD distinction becomes clearer when onset and duration are represented as separate temporal regions of one exposure–response curve. Early absorption and distribution influence the approach toward effect, whereas exposure persistence, metabolism, clearance, elimination, and pharmacodynamic response influence the later decline. A change in the ascending phase can shift onset without necessarily changing the elimination slope. Conversely, a change in clearance can alter persistence without materially changing early absorption. The onset definition, duration definition, pkpd overview, onset absorption phase, onset distribution phase, duration metabolism, and duration elimination concepts therefore provide complementary rather than redundant descriptions. This framework avoids reducing onset to a single speed label or duration to a single persistence label. It instead identifies the biological and pharmacokinetic processes responsible for each part of the timing pattern.
Onset is the emergence of pharmacological effect from an ascending exposure–response trajectory. The time to effect concept describes the interval between drug input and a defined response, but that interval is generated by multiple overlapping processes. Onset plasma levels describe the early systemic concentration profile after absorption. The onset cmax relation connects this rising profile with peak concentration, although Cmax is not itself an onset measurement. Oral sildenafil must first undergo gastrointestinal handling and absorption before systemic exposure develops. The timing of that input influences the ascending concentration–time curve. Onset food impact and onset fatty food delay describe meal-related influences on absorption kinetics. Onset gastric emptying describes a gastrointestinal process that can affect when drug becomes available for intestinal absorption. These determinants influence early exposure rather than directly defining the pharmacodynamic response threshold.
Threshold crossing is a useful conceptual model for understanding how early exposure becomes effect. As sildenafil concentration rises, the concentration–effect relationship determines when a biological response becomes detectable or reaches a predefined response range. The threshold is not necessarily a universal fixed concentration because response can vary with the pharmacodynamic endpoint and the model used. Absorption establishes systemic input, while distribution contributes to movement between compartments and may influence the relationship between plasma and effect-site exposure. The time to effect therefore should not be equated with time to peak concentration. Likewise, the onset plasma levels profile describes exposure, not the complete biological response. Food-related changes in absorption can shift the early curve, but they do not automatically determine the later effect window. Onset is consequently an emergent PK/PD property that depends on the interaction between exposure development and pharmacodynamic response.
The principal onset determinants can be organized into a sequential chain. Gastric emptying and meal effects influence gastrointestinal input; absorption determines the rate and extent of systemic entry; plasma concentration rises according to input and disposition; distribution contributes to compartmental movement; and pharmacodynamics translates exposure into effect. The onset food impact, onset fatty food delay, and onset gastric emptying concepts describe different aspects of input timing. Onset plasma levels and the onset cmax relation describe early concentration behavior, while the time to effect concept connects that behavior to effect emergence. This chain explains why onset should be interpreted through measurable PK/PD mechanisms rather than a subjective label such as fast or slow. A change in one determinant can shift onset without proportionally changing duration.
| Onset Determinant | PK Basis | Timing Contribution |
|---|---|---|
| Gastric emptying | Movement of orally administered contents toward the intestinal absorption site | Can influence when systemic input begins and how quickly early exposure develops |
| Food effects | Meal-related changes in gastrointestinal handling and absorption kinetics | Can alter the timing and shape of the ascending concentration–time phase |
| Absorption rate | Rate at which sildenafil enters systemic circulation | Shapes the early plasma concentration rise and time to response-relevant exposure |
| Early plasma levels | Systemic concentration trajectory after absorption | Determines when exposure approaches a pharmacodynamically relevant range |
| Distribution | Movement between plasma and other body compartments | Contributes to the relationship between plasma exposure and effect-site exposure |
| Concentration–effect relationship | Pharmacodynamic translation of exposure into biological response | Determines when rising exposure becomes associated with detectable effect |
Duration describes persistence of pharmacologically relevant effect after onset has occurred. The effect window concept identifies the period during which exposure remains associated with a defined pharmacodynamic response. The duration effect window perspective distinguishes this functional interval from the total time sildenafil remains measurable in the body. The concentration–effect relationship determines how systemic exposure translates into response, while exposure persistence determines how long that relationship remains relevant. Metabolism, clearance, and elimination progressively reduce systemic drug exposure. The duration metabolism concept describes metabolic transformation, and the duration cyp3a4 concept identifies CYP3A4-related metabolism as a relevant disposition pathway. The duration elimination concept describes overall removal from the body. These mechanisms shape the descending exposure profile and contribute to the time during which effect remains pharmacologically relevant.
Duration is not identical to half-life or to the time until drug is completely eliminated. The duration half-life concept describes a characteristic decline in systemic concentration, whereas duration describes persistence of a defined pharmacodynamic effect. Duration plasma levels describe the concentration trajectory during the later phase, but concentration alone does not fully specify response. The concentration–effect relationship, distribution, and effect-site behavior can influence the relationship between exposure and biological activity. As concentrations decline, the response may diminish and eventually leave the defined effect window. This means that an effect window is a PD-oriented construct linked to exposure rather than a direct measure of total drug residence. Metabolism and elimination contribute to the decline, but they do not necessarily determine the exact moment at which the pharmacodynamic response becomes undetectable. Duration is therefore best understood as the persistence of relevant exposure–response activity.
The duration sequence can be represented as exposure persistence followed by progressive decline. After the early exposure phase, metabolism and clearance contribute to falling plasma concentrations. The duration effect window describes the period during which the concentration–response relationship remains associated with the defined effect. Duration metabolism and duration cyp3a4 describe metabolic influences on disposition, while duration elimination describes the overall removal process. The duration half-life and duration plasma levels concepts describe complementary aspects of the declining concentration profile. This framework explains why onset and duration need not change together. A shift in absorption can alter the ascending phase while leaving later elimination relatively similar. A change in clearance can alter persistence without necessarily changing the initial input phase. Duration is therefore a distinct temporal construct within the same PK/PD trajectory.
Onset and duration are compared by examining different intervals of the same PK/PD time course. Onset describes the transition from input and rising exposure to pharmacological effect, whereas duration describes persistence of relevant effect after that transition. The onset duration ratio is a descriptive relationship between these intervals. It does not represent an independent biological mechanism. The onset duration balance concept emphasizes that the ascending and persistent phases are shaped by overlapping but nonidentical determinants. Absorption and early exposure are particularly relevant to onset, while metabolism, clearance, elimination, and the concentration–effect relationship become particularly relevant to duration. The onset duration optimization concept can describe analytical consideration of these temporal properties, but mechanistic interpretation should remain separate from subjective preference. A timing profile is best represented as a continuous exposure–response curve rather than as isolated labels.
Variability can change the relationship between onset and duration without affecting both equally. The onset duration variability concept includes differences in absorption, distribution, metabolism, clearance, elimination, interactions, and pharmacodynamic sensitivity. The onset duration graph analysis perspective separates the ascending exposure phase, response-emergence region, effect window, and declining phase. This distinction helps identify whether a timing difference is primarily an onset phenomenon, a duration phenomenon, or a change affecting both. For example, a change in absorption can shift the early curve, whereas a change in clearance can alter the later decline. The onset duration ratio may change in either situation, but the ratio alone cannot identify the underlying cause. A mechanistic comparison therefore requires attention to the PK and PD layers that generated the observed timing pattern.
The onset–duration relationship can be summarized through four components: early input and absorption, exposure and distribution, effect emergence, and persistence with decline. The onset duration balance describes the relationship between early and later timing, while the onset duration ratio provides a descriptive comparison of intervals. The onset duration optimization concept describes analytical examination of the profile, and the onset duration variability concept explains why profiles can differ. The onset duration graph analysis framework makes the separation visible by showing that onset and duration occupy different regions of one curve. This avoids treating onset as the inverse of duration. The balance is a property of the complete PK/PD trajectory, not a single numerical parameter or subjective judgment.
| Timing Component | PK/PD Basis | Interpretation |
|---|---|---|
| Onset interval | Absorption, early systemic exposure, distribution, and concentration–effect relationship | Represents the approach to pharmacologically relevant effect |
| Peak-related phase | Rising exposure followed by maximal or near-maximal systemic concentration | Connects early exposure development with the later persistence phase |
| Effect window | Pharmacodynamic activity associated with relevant exposure | Defines the functional period of effect rather than total drug residence |
| Duration interval | Exposure persistence, metabolism, clearance, elimination, and PD decline | Represents persistence of relevant effect after onset |
| Onset–duration ratio | Relationship between onset timing and persistence interval | Provides a descriptive comparison, not an independent mechanism |
| Timing variability | Changes across absorption, disposition, interactions, and response | Explains why onset and duration can differ across PK/PD conditions |
PK/PD timing models connect drug concentration over time with biological effect over time. The pkpd timing models framework begins with pharmacokinetic input and disposition, producing a concentration–time profile. A pharmacodynamic component then relates exposure to response, allowing effect emergence and decline to be represented. For sildenafil, the model can distinguish the ascending exposure phase from the later persistence and elimination phase. Absorption, distribution, metabolism, clearance, and elimination shape the exposure trajectory, while the concentration–effect relationship translates exposure into biological activity. This approach avoids treating onset and duration as independent measurements. Onset is represented by the transition into a response-relevant range, while duration is represented by persistence of relevant response as exposure declines. The model can be conceptual or quantitative, but its central purpose is to connect observable timing with the processes that generate it.
The relationship between onset and duration becomes more informative when variability is represented within the model. The variability factors framework describes changes in absorption, distribution, metabolism, elimination, interactions, and pharmacodynamic response. These changes can shift the ascending curve, the descending curve, or both. The timing consistency concept describes reproducibility of the resulting temporal pattern across observations. A model can therefore distinguish a change in early exposure from a change in later persistence, even when both produce a different overall timing profile. The clinical timing perspective translates these mechanistic relationships into observed timing expectations without turning them into subjective guarantees. A population-level timing distribution can reflect variation in multiple PK/PD layers simultaneously. This is why clinical timing descriptions should be interpreted in relation to the underlying exposure–response model rather than as universal clock-time rules.
The onset duration pharmacology framework connects the timing relationship to the underlying drug mechanisms. Onset reflects the path from input through absorption, distribution, early plasma exposure, and response emergence. Duration reflects exposure persistence, metabolism, clearance, elimination, and the decline of pharmacodynamic activity. The pkpd timing models framework provides a way to represent these linked processes, while variability factors and timing consistency describe how the pattern can differ across conditions. The clinical timing perspective connects model outputs to observed timing expectations. These models are descriptive tools for understanding temporal relationships, not subjective rankings of onset or duration. A mechanistic interpretation asks which PK/PD layer explains a timing difference and whether the change primarily affects effect emergence, persistence, or both.
Onset is the emergence of a pharmacological effect after drug exposure develops. For sildenafil, the process begins with oral input, followed by absorption into systemic circulation. Plasma concentrations rise, distribution contributes to movement between compartments, and the concentration–effect relationship determines when a biological response becomes detectable or enters a defined response-relevant range. This transition is often described conceptually as threshold crossing, although a threshold need not be a single universal concentration. Onset is therefore an emergent PK/PD event rather than a single isolated parameter. Time to peak concentration is not identical to onset, because peak concentration occurs at a different point in the exposure trajectory. The timing of effect emergence depends on the interaction between absorption, early exposure, distribution, and pharmacodynamic response. These mechanisms provide the basis for understanding onset without relying on subjective timing labels.
Duration describes how long a defined pharmacological effect persists after it has emerged. For sildenafil, duration depends on the persistence of relevant exposure and the concentration–effect relationship. Metabolism, clearance, and elimination progressively reduce systemic exposure, while distribution and pharmacodynamic response influence how that decline translates into biological activity. An effect window is therefore different from the total time that drug remains measurable in the body. Half-life describes a characteristic concentration decline, but it is not identical to the duration of pharmacodynamic effect. The relationship between plasma concentration and response can vary according to the pharmacodynamic endpoint being considered. Duration is best understood as a functional PK/PD interval rather than a direct measure of complete drug removal. This distinction explains why onset and duration are related but mechanistically different temporal constructs.
Pharmacokinetics describes the movement of sildenafil through the body, including absorption, distribution, metabolism, and elimination. Pharmacodynamics describes the biological response associated with drug exposure and the relationship between concentration and effect. Timing emerges from the interaction of these layers. During the early phase, absorption establishes systemic input and plasma concentration rises. Distribution contributes to compartmental movement and can influence the relationship between plasma and effect-site exposure. The pharmacodynamic response becomes associated with exposure as concentration enters a response-relevant range. During the later phase, metabolism, clearance, and elimination reduce exposure, while the response declines according to the concentration–effect relationship. These processes are connected rather than independent. PK/PD basics therefore explain why onset and duration are different portions of one time course and why a change in one layer can alter timing without producing an equivalent change in every other layer.
Absorption and distribution describe different pharmacokinetic processes. Absorption is the movement of sildenafil from the site of administration into systemic circulation. For an oral drug, gastrointestinal handling influences when systemic input begins and how quickly exposure develops. Distribution is the movement of drug between the bloodstream and other body compartments after systemic entry. Absorption primarily establishes the input that drives the early plasma concentration rise. Distribution contributes to where drug moves and can influence the relationship between plasma exposure and exposure at relevant effect sites. Neither process alone defines onset. The pharmacodynamic response depends on the resulting exposure and the concentration–effect relationship. A change in absorption can shift the early concentration–time curve, while a distributional change may alter the relationship between plasma concentration and biological response. Both processes are relevant, but they contribute through different mechanisms.
Metabolism and elimination are related but distinct pharmacokinetic concepts. Metabolism refers to biochemical transformation of sildenafil into other chemical species through enzymatic processes. Elimination is the broader process by which drug is removed from the body and includes metabolic and excretory pathways. In timing analysis, metabolism can change the amount of parent sildenafil remaining in systemic circulation and therefore influence the exposure profile. Elimination describes the overall removal process and is commonly reflected in clearance and concentration–time behavior. A metabolic reaction can contribute to elimination, but metabolism is not identical to complete drug removal. This distinction matters for duration because pharmacodynamic activity may decline as exposure decreases even though some drug remains measurable. Changes affecting elimination can alter persistence without necessarily changing the initial absorption phase. Metabolism and elimination therefore describe related but separate mechanisms in the later PK/PD trajectory.
An effect window is the period during which drug exposure is associated with a defined pharmacodynamic effect. It is different from the total time sildenafil remains detectable in the body. The effect window depends on both exposure and the concentration–response relationship. After absorption and distribution establish relevant exposure, the pharmacodynamic response can emerge and persist while concentrations remain within a response-associated range. As metabolism, clearance, and elimination reduce exposure, the response may decline and eventually leave the defined effect window. Because concentration–effect relationships can differ according to the biological endpoint, an effect window is tied to the effect being measured. It should not be treated as a universal boundary independent of the pharmacodynamic definition. In timing interpretation, the effect window connects measurable PK exposure with the persistence of a defined biological response.
Onset and duration should be compared as distinct intervals within a shared PK/PD trajectory. Onset concerns the transition from drug input and rising exposure to the emergence of pharmacological effect. Duration concerns persistence of relevant effect after that transition. The two intervals are related because they arise from the same exposure profile, but their dominant determinants can differ. Absorption and early concentration development are especially important to onset, while metabolism, clearance, elimination, exposure persistence, and the concentration–response relationship become particularly important to duration. A comparison should not treat duration as simply the opposite of onset. A faster early exposure rise does not necessarily produce a proportionate change in the later elimination profile. Conversely, altered clearance may affect persistence without changing initial absorption. Ratio and balance concepts describe the relationship between intervals but do not independently explain their mechanisms.
Timing consistency describes how reproducibly a PK/PD timing pattern occurs across observations or conditions. It does not mean that an identical clock-time response must occur every time. Sildenafil timing can vary because absorption, distribution, metabolism, clearance, interactions, physiological conditions, and pharmacodynamic sensitivity can differ. If the early concentration rise changes, onset may shift. If exposure persists differently during the elimination phase, duration may change. Timing consistency therefore depends on the stability of the processes that generate the concentration–time and effect–time curves. A consistent mechanism can still produce variation because biological systems are not identical across observations. Conversely, a large timing difference does not identify a single cause without supporting evidence. Timing consistency is best interpreted as a property of reproducibility of the complete temporal pattern rather than a guarantee of a fixed onset or duration.
Variability can arise from multiple pharmacokinetic and pharmacodynamic layers. During onset, gastrointestinal handling, gastric emptying, food-related effects, absorption rate, early plasma exposure, and distribution can influence when effect becomes apparent. During duration, metabolic activity, clearance, elimination, distribution, and the concentration–effect relationship can influence how long relevant activity persists. Drug interactions can modify exposure by changing metabolic or disposition processes. Physiological differences may affect more than one layer simultaneously, making it difficult to attribute an observed timing difference to a single mechanism without supporting data. Importantly, variability in onset does not necessarily imply equivalent variability in duration. A factor that primarily changes absorption may shift the early curve while leaving later elimination relatively similar. A factor affecting clearance may alter persistence while leaving initial absorption largely unchanged. Timing variability is therefore best interpreted by locating the affected portion of the PK/PD trajectory.
PK/PD timing models connect drug concentration over time with biological effect over time. A basic model begins with pharmacokinetic input and disposition, producing a concentration–time curve. A pharmacodynamic component then relates concentration to response, allowing effect emergence and decline to be represented. More detailed models can include distribution compartments, effect-site equilibration, nonlinear concentration–effect relationships, and delays between plasma concentration and response. For onset analysis, the model emphasizes the ascending exposure phase and the point at which response becomes pharmacologically meaningful. For duration analysis, it emphasizes persistence of relevant exposure and the decline of response as concentrations fall. Such models help distinguish different mechanisms that can produce similar observed timing. They are useful for interpreting onset, duration, variability, and timing consistency without reducing the complete PK/PD trajectory to a single clock-time value.